A huge number of modern therapeutic modalities must be administered parenterally in order to achieve systemic action, including biologics, oligonucletotides and cell & gene therapy. <br/>Whilst formulations for antibodies become more established and commoditized, novel formats including bispecifics or fusion proteins may pose different challenges. Viral vector or cell therapy formulations have to a large extend not been exploited at all, which often leads to (deep) frozen storage of such products, leading to significant challenges for distribution and usability alike. <br/>This talk aims to discuss some pharmaceutical challenges - and opportunities - for the development of modern biologics, including therapeutic proteins, gene and cell therapy.

Challenges & opportunities for the development of parenteral products of novel modalities

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.